Market Cap 8.97M
Revenue (ttm) 0.00
Net Income (ttm) -16.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 10,206
Avg Vol 305,372
Day's Range N/A - N/A
Shares Out 917,000.00
Stochastic %K 59%
Beta 1.53
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 837 3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
Vedran1
Vedran1 Mar. 14 at 2:01 PM
$RNAZ In WSJ yesterday: "White House Puts RFK Jr.’s HHS on Tighter Leash After MAHA Setbacks": "...The White House is more tightly controlling the messaging and policies—including around vaccines—coming from the Department of Health and Human Services ahead of the midterm elections, according to people familiar with the matter. Aides close to President Trump decided to take a more active role in managing Robert F. Kennedy Jr. department in the face of polling that shows his vaccine moves are unpopular, the people said. Although Trump brought Kennedy into his administration with the promise that the vaccine skeptic and ultraprocessed-food critic could “go wild on health,” administration officials grew increasingly frustrated with what they viewed as foul-ups inside Kennedy’s department, according to people familiar with the matter. Aides close to Trump grew worried that perceived disorganization and a focus on vaccines could damage the president’s party in November, ..."
1 · Reply
Vedran1
Vedran1 Mar. 7 at 7:46 PM
$RNAZ The last year was THE BEST RNAZ year for me since I opened an IRA account on July 2024. Other non-IRA account opened on Sep 2023 could buy a nice dinner for two if I would close it now at a cost bases of ~40k with about the same loss. Here is the IRA account image. I am just adding to IRA account for the last year.
1 · Reply
Vedran1
Vedran1 Mar. 7 at 8:14 AM
$RNAZ In the WSJ article today: "FDA’s Controversial Vaccines Chief Will Leave the Agency - Dr. Vinay Prasad will depart in April, after a year leading the division that approves vaccines and biotech drugs": "...Prasad has been a source of controversy at the FDA—and headache for the Trump administration—for months. He recently was involved in a series of regulatory reversals for rare-disease drugs, upsetting patients and families as well as pharmaceutical companies, The Wall Street Journal has reported. ... He refused in February to consider a flu-shot application from Moderna, setting off a flurry of meetings and calls with White House officials. The FDA quickly reversed course, agreeing to review Moderna’s application after the company agreed to another confirmatory study in an older age group. ...
2 · Reply
Hovius
Hovius Mar. 6 at 5:39 PM
$RNAZ This is why we are here… https://m.novinite.com/view_news.php?id=236774
1 · Reply
Zeusgodmd
Zeusgodmd Mar. 6 at 3:05 PM
$RNAZ I see it as an additional cancer treatment. The company was given 10 million dollars of our stock to ride a cure or buyout potentially 10 to 30 or 60 times current price. With additional treatment we probably made this stock worth 300 million more for a buyout that goes to all the shareholders and this new company
2 · Reply
Hovius
Hovius Mar. 5 at 9:18 PM
$RNAZ Is this dilution?
1 · Reply
ezgg2023
ezgg2023 Mar. 3 at 9:26 PM
$RNAZ looks primed for a run up after the news
0 · Reply
notreload_ai
notreload_ai Mar. 3 at 3:04 PM
$RNAZ announces an exclusive license for advanced cancer immunotherapy tech from Unleash, targeting hard-to-treat bladder cancer and more, in an all-stock deal to expand their pipeline. https://notreload.xyz/transcode-licenses-oncolytic-immunotherapy-for-bladder-cancer/
0 · Reply
Scoty_D
Scoty_D Mar. 3 at 1:34 PM
0 · Reply
Hovius
Hovius Mar. 3 at 1:24 PM
$RNAZ WTF is this chit??! More dilution…
1 · Reply
Latest News on RNAZ
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 11 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split


TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 2 years ago

TransCode Therapeutics Open Letter to Shareholders


TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split


Vedran1
Vedran1 Mar. 14 at 2:01 PM
$RNAZ In WSJ yesterday: "White House Puts RFK Jr.’s HHS on Tighter Leash After MAHA Setbacks": "...The White House is more tightly controlling the messaging and policies—including around vaccines—coming from the Department of Health and Human Services ahead of the midterm elections, according to people familiar with the matter. Aides close to President Trump decided to take a more active role in managing Robert F. Kennedy Jr. department in the face of polling that shows his vaccine moves are unpopular, the people said. Although Trump brought Kennedy into his administration with the promise that the vaccine skeptic and ultraprocessed-food critic could “go wild on health,” administration officials grew increasingly frustrated with what they viewed as foul-ups inside Kennedy’s department, according to people familiar with the matter. Aides close to Trump grew worried that perceived disorganization and a focus on vaccines could damage the president’s party in November, ..."
1 · Reply
Vedran1
Vedran1 Mar. 7 at 7:46 PM
$RNAZ The last year was THE BEST RNAZ year for me since I opened an IRA account on July 2024. Other non-IRA account opened on Sep 2023 could buy a nice dinner for two if I would close it now at a cost bases of ~40k with about the same loss. Here is the IRA account image. I am just adding to IRA account for the last year.
1 · Reply
Vedran1
Vedran1 Mar. 7 at 8:14 AM
$RNAZ In the WSJ article today: "FDA’s Controversial Vaccines Chief Will Leave the Agency - Dr. Vinay Prasad will depart in April, after a year leading the division that approves vaccines and biotech drugs": "...Prasad has been a source of controversy at the FDA—and headache for the Trump administration—for months. He recently was involved in a series of regulatory reversals for rare-disease drugs, upsetting patients and families as well as pharmaceutical companies, The Wall Street Journal has reported. ... He refused in February to consider a flu-shot application from Moderna, setting off a flurry of meetings and calls with White House officials. The FDA quickly reversed course, agreeing to review Moderna’s application after the company agreed to another confirmatory study in an older age group. ...
2 · Reply
Hovius
Hovius Mar. 6 at 5:39 PM
$RNAZ This is why we are here… https://m.novinite.com/view_news.php?id=236774
1 · Reply
Zeusgodmd
Zeusgodmd Mar. 6 at 3:05 PM
$RNAZ I see it as an additional cancer treatment. The company was given 10 million dollars of our stock to ride a cure or buyout potentially 10 to 30 or 60 times current price. With additional treatment we probably made this stock worth 300 million more for a buyout that goes to all the shareholders and this new company
2 · Reply
Hovius
Hovius Mar. 5 at 9:18 PM
$RNAZ Is this dilution?
1 · Reply
ezgg2023
ezgg2023 Mar. 3 at 9:26 PM
$RNAZ looks primed for a run up after the news
0 · Reply
notreload_ai
notreload_ai Mar. 3 at 3:04 PM
$RNAZ announces an exclusive license for advanced cancer immunotherapy tech from Unleash, targeting hard-to-treat bladder cancer and more, in an all-stock deal to expand their pipeline. https://notreload.xyz/transcode-licenses-oncolytic-immunotherapy-for-bladder-cancer/
0 · Reply
Scoty_D
Scoty_D Mar. 3 at 1:34 PM
0 · Reply
Hovius
Hovius Mar. 3 at 1:24 PM
$RNAZ WTF is this chit??! More dilution…
1 · Reply
DekmarTrades
DekmarTrades Mar. 3 at 1:03 PM
$RNAZ Exclusive, Worldwide, Fully Paid-Up Royalty-Free License
0 · Reply
StockNews_Live
StockNews_Live Mar. 3 at 1:02 PM
$RNAZ TransCode Therapeutics, Inc. announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. for three Unleash drug candid…
0 · Reply
HorsePicks
HorsePicks Mar. 3 at 1:01 PM
$RNAZ TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 26 at 8:38 PM
$RNAZ REQUIRE YOUR SERVICES SHORTLY
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 10:54 PM
$RNAZ RSI: 57.73, MACD: 0.1706 Vol: 0.70, MA20: 9.73, MA50: 8.92 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ShadowSnake
ShadowSnake Feb. 25 at 8:57 PM
$RNAZ out … lost $3,900… GLTYA
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 25 at 2:18 AM
$RNAZ Current Stock Price: $9.74
0 · Reply
ShadowSnake
ShadowSnake Feb. 24 at 3:35 PM
$RNAZ looks like today is the day I swallow my pride and take the loss… pos stock…GLTYA
2 · Reply
Scoty_D
Scoty_D Feb. 24 at 2:12 PM
0 · Reply
TheMorningStew
TheMorningStew Feb. 24 at 11:28 AM
$RNAZ could go 13+ soon
1 · Reply
Hovius
Hovius Feb. 24 at 11:14 AM
$RNAZ good news.. will it drop? https://ir.transcodetherapeutics.com/2026-02-23-TransCode-Therapeutics-Announces-Publication-of-Preclinical-Testing-of-RIG-I-Immunotherapeutic-Candidate-Supporting-Further-Development
0 · Reply
ShadowSnake
ShadowSnake Feb. 19 at 9:35 PM
0 · Reply